Plasma Metabolites as Mediators Between Gut Microbiota and Parkinson's Disease: Insights from Mendelian Randomization

Jianzhun Chen1, Liuhui Zhu1, Fang Wang1

  • 1Department of Neurology, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, 650032, P.R. China.

Molecular Neurobiology
|February 17, 2025
PubMed

Insights

Gut microbiota and plasma metabolites play causal roles in Parkinson's disease (PD). Specific metabolites mediate the link between gut bacteria and PD risk, revealing new pathogenic mechanisms.

Area of Science:

  • Neuroscience
  • Microbiology
  • Metabolomics

Background:

  • Emerging evidence links plasma metabolites and gut microbiota (GM) to Parkinson's disease (PD) pathogenesis.
  • The precise causal pathways, particularly the mediating role of metabolites in the GM-PD axis, remain incompletely understood.

Purpose of the Study:

  • To investigate the causal relationships between GM, plasma metabolites, and PD using Mendelian randomization (MR).
  • To elucidate the potential mediating effects of plasma metabolites in the association between GM and PD risk.

Main Methods:

  • Utilized summary statistics from genome-wide association studies (GWAS) for metabolites (N=8299), GM (N=18,340), and PD (Ncase=33,674; Ncontrol=449,056).
  • Employed two-step/mediation MR (TSMR) to assess mediation pathways.
  • Identified 54 genetic traits causally associated with PD development.

Main Results:

  • TSMR analysis revealed that ceramide mediates the relationship between Clostridium sensu stricto 1 and PD risk (15.35% mediation).
  • 7-Alpha-hydroxy-3-oxo-4-cholestenoate was found to mediate the association between Eubacterium xylanophilum group and PD risk (11.04% mediation).

Conclusions:

  • This MR study establishes intrinsic causal links among GM, plasma metabolites, and PD.
  • Findings provide novel insights into the pathogenic mechanisms of PD, highlighting the crucial roles of gut microbiota and specific metabolites.

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
187
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
429
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
26